drugset / Trial / NCT03962855
Thromboxane Receptor Antagonist to Improve Endothelial Function
Phase 2
Completed
57 enrolled
Jeffrey Rade
American Heart Association · collabCumberland Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.
Timeline
- Start
- 2019-09-20
- Primary completion
- 2022-11-07
- Completion
- 2022-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ifetroban | Small molecule | 250 mg | Oral |